Getting to Know Benjamin R. Lin, MD
Board-certified ophthalmologist and retina specialist Benjamin R. Lin, MD, joined Texas Retina in September and cares for patients in our Dallas Main, Dallas North and Plano offices. He came to us from
read more
Dr. Abbey Spoke About the VERONA Diabetic Macular Edema Clinical Trial at The Retina Society’s Annual Meeting
On behalf of the VERONA study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered a presentation titled “VERONA: End-of-Study Results from a Phase 2 Trial of EYP-1901 (vorolanib intravitreal insert) versus Aflibercept
read more
Why We Dilate Your Eyes
Patients often ask why we must dilate their eyes. A dilated retina exam is essential to properly diagnosing and monitoring a number of retina conditions, including diabetic retinopathy, macular degeneration and retinal tears or detachment. Your
read more
Dr. Abbey Delivered On-Demand Presentation About the PHOTON DME Study for ASRS 2025 Meeting
On behalf of the PHOTON study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered an on-demand presentation titled “Differential Anatomic Response to Aflibercept 8 mg vs 2 mg During Matched Dosing Phase
read more
June is Fireworks Eye Safety Awareness Month
Summer is here, and for many that means outdoor celebrations that include fireworks, especially around the 4th of July. Unfortunately, this also means an increase in eye injuries. Here are a few
read more
Initial Results of Phase Ib LOTUS Clinical Trial on Potential New Diabetic Macular Edema Treatment Released
On June 9, 2025, Eluminex Biosciences Limited, a clinical-stage protein therapeutics company, announced positive topline safety, tolerability, and pharmacodynamic data from the multicenter LOTUS Part 1 clinical trial of EB-105 in patients
read more
Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article
Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic
read more


